Linezolid B. Braun Melsungen Ag

Linezolid, the active ingredient in Linezolid B. Braun Melsungen Ag, is an oxazolidinone presented as an injectable solution for intravenous use. It treats complicated skin and skin structure infections, community‑acquired bacterial pneumonia, nosocomial pneumonia and MRSA infections in adult patients.

GNH USA supplies Linezolid B. Braun Melsungen Ag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Linezolid is indicated for bacterial infections that are resistant to other antibiotics, particularly those affecting the skin, lungs, and caused by MRSA. - Complicated skin and skin structure infections: effective against Gram‑positive pathogens, including MRSA, reducing infection severity. - Community‑acquired bacterial pneumonia: provides bacterial clearance and clinical improvement in adult patients. - Nosocomial pneumonia: treats hospital‑acquired lung infections caused by susceptible organisms. - Methicillin‑resistant Staphylococcus aureus (MRSA) infections: eradicates MRSA strains in various infection sites.

Linezolid may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, usually self‑limited. - Headache: transient cranial discomfort. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Thrombocytopenia: significant drop in platelet count, may require monitoring. - Peripheral neuropathy: nerve damage presenting as tingling or numbness, potentially irreversible. - Serotonin syndrome: risk when combined with serotonergic agents, characterized by agitation, hyperthermia, and autonomic instability. - Lactic acidosis: rare metabolic disturbance with elevated lactate levels.

When prescribing linezolid, clinicians should consider several safety measures. - Renal impairment: adjust therapy and monitor renal function. - Hepatic dysfunction: use with caution in patients with liver disease. - Hematologic monitoring: regular CBCs recommended due to risk of thrombocytopenia. - Serotonergic drugs: avoid concomitant use to prevent serotonin syndrome. - Pregnancy and lactation: safety not established; weigh benefits against risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Linezolid interacts with several drug classes that may alter safety or efficacy.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs): may precipitate serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Tricyclic antidepressants: increased serotonergic activity.

Moderate Interactions (Monitor Closely): - Warfarin: linezolid may enhance anticoagulant effect, monitor INR. - Theophylline: possible increased plasma levels, monitor for toxicity. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of bleeding when combined with thrombocytopenia.